Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Indication
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Indication

1 evidence topic · 1 source

European indication

“desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.” (opens the source at this quote in a new tab)